Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Venture Fund Takes Aim at Japanese Bioventures (Japan)

This article was originally published in PharmAsia News

Executive Summary

The Novartis Venture Fund, established by Swiss pharmaceutical giant Novartis, has recently been looking to invest in a number of Japanese entities. According to fund representatives, it is looking to invest in drugmakers, medical equipment manufacturers, and diagnostic drug producers. Before making any decisions, a Novartis team will determine if a start-up company has the right combination of technology and prospective products that would fulfill a market need. Asides from companies, the fund is also looking to invest in Japanese universities and research institutes with the goal of aiding them to get into business. (Click here for more - May Require Paid Subscription

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel